Kristin Wickens

Kristin Wickens

Auto-generated profile, based on publicly available information

Kristin Wickens

Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KWKristin Wickens
Kristin Wickens
PBPeter N. Black
Peter N. Black
TSThorsten V. Stanley
Thorsten V. Stanley
EMEdwin Mitchell
Edwin Mitchell
PFPenny Fitzharris
Penny Fitzharris
JCJulian Crane
Julian Crane

28 March 2017 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
KWKristin L. Wickens
Kristin L. Wickens
CBChristine A. Barthow
Christine A. Barthow
RMRinki Murphy
Rinki Murphy
PAPeter R. Abels
Peter R. Abels
RMRobyn M. Maude
Robyn M. Maude
JCJulian Crane
Julian Crane
The study aims to assess whether supplementation with the probiotic Lactobacillus rhamnosus HN001 (HN001) can reduce the prevalence of gestational diabetes mellitus (GDM). A double-blind, randomised, placebo-controlled parallel trial was conducted in New Zealand (NZ) (Wellington and Auckland). Pregnant women with a personal or partner history of atopic disease were randomised at 14–16 weeks’ gestation to receive HN001 (6×109 colony-forming units) (n 212) or placebo (n 211) daily. GDM at 24–30 weeks was assessed using the definition of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) (fasting plasma glucose ≥5·1 mmol/l, or 1 h post 75 g glucose level at ≥10 mmol/l or at 2 h ≥8·5 mmol/l) and NZ definition (fasting plasma glucose ≥5·5 mmol/l or 2 h post 75 g glucose at ≥9 mmol/l). All analyses were intention-to-treat. A total of 184 (87 %) women took HN001 and 189 (90 %) women took placebo. There was a trend towards lower relative rates (RR) of GDM (IADPSG definition) in the HN001 group, 0·59 (95 % CI 0·32, 1·08) (P=0·08). HN001 was associated with lower rates of GDM in women aged ≥35 years (RR 0·31; 95 % CI 0·12, 0·81, P=0·009) and women with a history of GDM (RR 0·00; 95 % CI 0·00, 0·66, P=0·004). These rates did not differ significantly from those of women without these characteristics. Using the NZ definition, GDM prevalence was significantly lower in the HN001 group, 2·1 % (95 % CI 0·6, 5·2), v. 6·5 % (95 % CI 3·5, 10·9) in the placebo group (P=0·03). HN001 supplementation from 14 to 16 weeks’ gestation may reduce GDM prevalence, particularly among older women and those with previous GDM.

15 June 2012 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
KWK. Wickens
K. Wickens
PBP. Black
P. Black
TST. V. Stanley
T. V. Stanley
EME. Mitchell
E. Mitchell
CBC. Barthow
C. Barthow
JCJ. Crane
J. Crane

20 August 2013 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
KWK. Wickens
K. Wickens
TST. V. Stanley
T. V. Stanley
EME. A. Mitchell
E. A. Mitchell
CBC. Barthow
C. Barthow
PFP. Fitzharris
P. Fitzharris
JCJ. Crane
J. Crane

14 November 2018 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
KWKristin Wickens
Kristin Wickens
CBChristine Barthow
Christine Barthow
EMEdwin A. Mitchell
Edwin A. Mitchell
JKJanice Kang
Janice Kang
NZNoleen van Zyl
Noleen van Zyl
JCJulian Crane
Julian Crane

18 July 2008 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
KWK. Wickens
K. Wickens
TIT. Ingham
T. Ingham
MEM. Epton
M. Epton
PPP. Pattemore
P. Pattemore
ITI. Town
I. Town
TGthe New Zealand Asthma and Allergy Cohort Study Group
the New Zealand Asthma and Allergy Cohort Study Group